Treatment of elderly patients with refractory/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak
| Autor: | Fernando Sérgio Blumm Ferreira, Flávia Dias Xavier, Rodrigo Martins Abreu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty refractory/relapsed elderly 03 medical and health sciences 0302 clinical medicine Quality of life (healthcare) Refractory Health care Medicine adherence Adverse effect Intensive care medicine Multiple myeloma Polypharmacy business.industry Outbreak healthcare medicine.disease multiple myeloma 030104 developmental biology Oncology 030220 oncology & carcinogenesis Research Perspective business Patient education |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | Once the treatment of refractory/relapsed multiple myeloma in the elderly is greatly influenced by the adherence of patients and family members, clinicians should be aware of patients' behavior and lifestyle, as it may influence the individual treatment plan for each patient. Furthermore, treatment with oral chemotherapy is of special value during the COVID-19 outbreak. Multidisciplinary healthcare involvement is crucial in the management of polypharmacy, adverse events and dose adjustment due to comorbidities and natural loss of renal function with age. Oral drugs simplify intake, reduce hospital visits, and improve autonomy and quality of life. However, although oral drugs have advantages, they also transfer control and responsibility from the healthcare professional to the patient, who must be able to understand and follow the directions given. Therefore, patient education and communication with healthcare professionals are critical for adherence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|